| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | alpha-v beta-3 integrin |
| Clinical data | |
| Trade names | Vitaxin |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
  (what is this?)
| |
Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3. It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis. It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.
Vitaxin is safe for humans. It has little effect on advanced cancer.